» Articles » PMID: 24012176

Activation of Kynurenine Pathway in Ex Vivo Fibroblasts from Patients with Bipolar Disorder or Schizophrenia: Cytokine Challenge Increases Production of 3-hydroxykynurenine

Overview
Journal J Psychiatr Res
Specialty Psychiatry
Date 2013 Sep 10
PMID 24012176
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Accumulating data suggest a causative link between immune stimulation, disturbed metabolism of tryptophan, and pathogenesis of bipolar disorder and schizophrenia. The goal of this study was to examine the production of kynurenic acid (KYNA), 3-hydroxykynurenine (3-HK) and the expression of kynurenine pathway enzymes involved in their synthesis and metabolism in cultured skin fibroblasts obtained from patients with bipolar disorder, schizophrenia or from healthy control individuals. The assessment was performed under basal conditions or following treatment with interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, or their combinations, in cells exposed to exogenous kynurenine. In both groups of patients, the baseline production of KYNA and 3-HK was increased, as compared to control subjects. Case-treatment analyses revealed significant interactions between bipolar case status and IL-1β, IL-6, IFN-γ + TNF-α, or IFN-γ + IL-1β, as well as between schizophrenia case status and IL-1β, IFN-γ + TNF-α, or IFN-γ + IL-1β, in terms of higher 3-HK. Noteworthy, no case-treatment interactions in terms of KYNA production were found. Observed changes did not appear to correlate with the expression of genes encoding kynurenine aminotransferases (KATs), kynureninase (KYNU) or kynurenine-3-monooxygenase (KMO). The single nucleotide polymorphisms (SNPs), rs1053230 and rs2275163, in KMO influenced KYNA levels yet did not explain the case-treatment discrepancies. In conclusion, our present findings indicate the utility of skin-derived fibroblasts for kynurenines research and support the concept of kynurenine pathway alterations in bipolar disorder and schizophrenia. The increase in ratio between neurotoxic 3-HK and neuroinhibitory/neuroprotective KYNA following exposure to cytokines may account for altered neurogenesis and structural abnormalities characteristic for both diseases.

Citing Articles

Impact of neuroinflammation on brain glutamate and dopamine signalling in schizophrenia: an update.

Nayak U, Manikkath J, Arora D, Mudgal J Metab Brain Dis. 2025; 40(2):119.

PMID: 39907868 PMC: 11799129. DOI: 10.1007/s11011-025-01548-3.


Neuroactive Kynurenines as Pharmacological Targets: New Experimental Tools and Exciting Therapeutic Opportunities.

Pocivavsek A, Schwarcz R, Erhardt S Pharmacol Rev. 2024; 76(6):978-1008.

PMID: 39304346 PMC: 11549936. DOI: 10.1124/pharmrev.124.000239.


A Review on the Role and Function of Cinnabarinic Acid, a "Forgotten" Metabolite of the Kynurenine Pathway.

Gawel K Cells. 2024; 13(5.

PMID: 38474418 PMC: 10930587. DOI: 10.3390/cells13050453.


KYNU-related transcriptome profile and clinical outcome from 2994 breast tumors.

Li Y, Wang M, Zhao L, Liang C, Li W Heliyon. 2023; 9(6):e17216.

PMID: 37383199 PMC: 10293725. DOI: 10.1016/j.heliyon.2023.e17216.


The Kynurenine Pathway-New Linkage between Innate and Adaptive Immunity in Autoimmune Endocrinopathies.

Krupa A, Kowalska I Int J Mol Sci. 2021; 22(18).

PMID: 34576041 PMC: 8469440. DOI: 10.3390/ijms22189879.